ClinicalTrials.gg
CompletedNCT06545903Updated May 6, 2025

Supraglottic Airways for Entrapped Trauma Patients

An interventional study of LMA Supreme and SLIPA in Airway Obstruction, sponsored by Uniwersytet Radomski im. Kazimierza Pułaskiego. Completed at 1 site in Poland. Open to participants aged 25 Years to 55 Years. Per ClinicalTrials.gov, last updated 2025-05-06.

Sponsored by Uniwersytet Radomski im. Kazimierza Pułaskiego · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
25 Years to 55 Years
Sex
All
01

Study summary

The aim of this clinical trial is to evaluate four supraglottic airway devices for ventilation in a simulated condition of an entrapped trauma patient with simultaneous cervical spine immobilisation. All the studied devices are evaluated by fully-qualified and experienced paramedics (both male and female). The main questions it aims to answer are:

  1. Which device requires the shortest time required to achieve a successful ventilation?
  2. What is the first attempt success rate of the studied devices?
  3. Which device is the easiest to use and the most user-friendly? Study participants will evaluate four different supraglottic devices in a restricted access to the entrapped trauma patient's airway. The maximum number of insertion attempts is limited to three per device.
Read the detailed description

A 10-minute lecture will be delivered before the start of the study. It will explain how to use the studied devices. Following the lecture all participants will be able to familiarise themselves with the equipment and practice for 30 minutes. A skill station will be set up containing an intubation manikin AT Kelly Torso (Laerdal Medical AS, Stavanger, Norway). A reduced movement of the cervical spine will be achieved by application of a Patriot® cervical collar (Össur hf., Reykjavik, Iceland). After completion of the initial practice the intubation manikin with the cervical collar on will be placed on and secured to the driver's seat of a medium-sized passenger car (FIAT S.p.A., Turin, Italy). The car will then be positioned on its left side and secured in place by firemen from a local fire brigade. The access to the manikin will only be allowed from the front i.e. through the opening created after removal of the windscreen. A single digit number will be allocated to each of the four studied devices i.e. 1 for the SLIPA device, 2 for the I-gel, 3 for the LMA Supreme and 4 for the LTS. Each study participant will be asked to randomly give a number (either 1, 2, 3 or 4) and will then be given the corresponding airway device to use. The maximum number of insertion attempts will be limited to three per device. The time required to insert the device and achieve a successful ventilation (Tiv) will be recorded. It will be measured using a stopwatch of a mobile phone (Apple Inc., Cupertino, California, USA). Efficacy of insertion/ventilation and the ease of use by the operator will also be assessed. The latter will be measured using an 11-point numerical rating scale (NRS) where 0 corresponds to a very difficult to use device and 10 indicates an easy to use and user-friendly device. A manual resuscitator (Ambu A/S, Ballerup, Denmark) will be used for ventilation and will be readily available to the paramedics. The study participants will perform all insertions with each of the four supraglottic airway devices. A failed insertion and ventilation is defined as an attempt during which the manikin cannot be ventilated or an attempt that lasted longer than 120 seconds. Only those who failed to ventilate will be allowed another attempt. All the obtained data will be analysed using Microsoft Office Excel 2021 spreadsheet (Microsoft Corporation, Redmond, WA, USA). The Kolmogorov-Smirnov test is utilised to determine whether the analysed variables matched the characteristics of a normal distribution. A paired Student t-test and the Wilcoxon signed-rank test will be used for data analysis. Based on our previous unpublished pilot study and assuming that the overall success rate of intubation in patients with a difficult airway would be 90% (α =0.05, 2-sided, β =0.1), 46 participants will be required. The final adjusted sample size, allowing a drop-out rate of about 10%, is 50 and this is the final number of participants enrolled into the study. A p-value of less than 0.05 (p\<0.05) is considered statistically significant.

02

Conditions studied

  • Airway Obstruction

Browse trials for

Keywords

  • Entrapped Trauma Patients
  • Airway Management
  • Paramedics
03

In context

Airway Obstruction

147 studies on the registry are indexed under Airway Obstruction; 25 are open to participants now.

This study's enrollment of 50 is close to the median of 53 across 92 interventional studies indexed under Airway Obstruction.

Browse Airway Obstruction studies →

Lead sponsor

Uniwersytet Radomski im. Kazimierza Pułaskiego is the lead sponsor of 4 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
25 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • fully-qualified paramedics
  • at least four years of practice after finishing paramedic training
  • active (working) paramedics

Exclusion criteria

Exclusion Criteria:

  • paramedics in training
  • retired paramedics
  • lack of written
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
50 participants (actual)

Study arms

  • Active comparator
    LMA Supreme Group

    Paramedics using the LMA Supreme airway device

    Device: LMA Supreme

  • Experimental
    Other Supraglottic Airway Group

    Paramedics using other supraglottic devices

    Device: SLIPA · Device: I-gel · Device: AuraGain

Interventions

  • DeviceLMA Supreme

    The device is inserted and the manikin ventilated

  • DeviceSLIPA

    The device is inserted and the manikin ventilated

  • DeviceI-gel

    The device is inserted and the manikin ventilated

  • DeviceAuraGain

    The device is inserted and the manikin ventilated

06

What researchers measure

Primary outcomes

  1. Successful ventilation time

    The time required to insert the device and achieve a successful ventilation

    Time frame: During procedure: 120 seconds

Secondary outcomes

  1. First attempt success rate of ventilation

    The efficacy of an evaluated supraglottic airway device

    Time frame: During procedure: 120 seconds

  2. The ease of use and user-friendliness

    Device evaluation using the numerical rating scale (NRS). It is an 11-point scale where 0 corresponded to a very difficult to use device and 10 indicated an easy to use and user-friendly device.

    Time frame: During procedure: 120 seconds

07

Study locations

1 site
  • University of Radom
    Radom, Mazowieckie 26-600, Poland
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2024 to primary completion in Sep 2024, 2 months.

Of 36 non-industry interventional studies with no phase under Airway Obstruction, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 37. This study's 2 months is below that.

Counting every sponsor, half of 44 studies reached it within 16 months; a quarter within 3 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2024
First posted
Aug 9, 2024
StartActual
Jul 1, 2024
Primary completionActual
Sep 1, 2024
CompletionActual
May 1, 2025
Last update
May 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06545903
Lead sponsor
Uniwersytet Radomski im. Kazimierza Pułaskiego
Responsible party
Sponsor
First posted
Aug 9, 2024
Start date
Jul 1, 2024
Primary completion
Sep 1, 2024
Completion
May 1, 2025
Last update
May 6, 2025

Study contacts

Dawid J Aleksandrowicz, PhD
principal investigator · University of Radom

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion